Investigating STAT3 as a Driver of Pathology in Periodontitis
2 other identifiers
observational
28
1 country
1
Brief Summary
Periodontitis is a prevalent inflammatory condition that destroys tooth-supporting structures. This condition is associated with pro-inflammatory mediators that utilize STAT3 as an activator of specific genes related to inflammation and tissue destruction. STAT3 has not been studied in the context of periodontitis in humans. We propose that STAT3 is associated with periodontitis. This knowledge might help to further our understanding of periodontitis pathology
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for all trials
Started Mar 2019
Typical duration for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
March 20, 2019
CompletedFirst Submitted
Initial submission to the registry
August 16, 2022
CompletedFirst Posted
Study publicly available on registry
August 18, 2022
CompletedPrimary Completion
Last participant's last visit for primary outcome
October 20, 2022
CompletedStudy Completion
Last participant's last visit for all outcomes
October 20, 2022
CompletedJanuary 30, 2023
January 1, 2023
3.6 years
August 16, 2022
January 26, 2023
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
STAT3 detection in gingival tissues
Detection of STAT3 in gingival tissues
1 day
Study Arms (2)
Healthy
Subjects without periodontitis
Periodontitis
Subjects with periodontitis
Interventions
Eligibility Criteria
Female and male adults living in Santiago, Chile.
You may qualify if:
- year-old, in good general health, and had no significant medical history.
- no history of diabetes or other diseases different than periodontitis.
You may not qualify if:
- Pregnancy and lactation
- Use of antibiotics, immunosuppressive agents, or probiotics within 3 months.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Faculty of Dentistry, University of Chile
Santiago, Chile
Biospecimen
gingival biopsies
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Design
- Study Type
- observational
- Observational Model
- OTHER
- Time Perspective
- CROSS SECTIONAL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Associate Professor
Study Record Dates
First Submitted
August 16, 2022
First Posted
August 18, 2022
Study Start
March 20, 2019
Primary Completion
October 20, 2022
Study Completion
October 20, 2022
Last Updated
January 30, 2023
Record last verified: 2023-01
Data Sharing
- IPD Sharing
- Will share
- Shared Documents
- STUDY PROTOCOL, CSR, ANALYTIC CODE
- Time Frame
- december 2022
All data specified in the informed consent will be shared in publications